Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Parkinsonism & Related Disorders

• Publication date

  2009-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1353-8020(09)70782-5PMID 20083009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• l‐DOPA‐induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia

  2010cited by this paper
• De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat.

  2009cited by this paper
• Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease

  2009cited by this paper
• Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.

  2009cited by this paper
• PET demonstrates reduced dopamine transporter expression in PD with dyskinesias

  2009cited by this paper
• BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson’s disease

  2009cited by this paper
• Genetic variation in brain-derived neurotrophic factor is associated with serotonin transporter but not serotonin-1A receptor availability in men.

  2009cited by this paper
• Impact of genetic variant BDNF (Val66Met) on brain structure and function.

  2008cited by this paper
• Interaction between BDNF and Serotonin: Role in Mood Disorders

  2008influential reference
• Behavioral Recovery in MPTP-Treated Monkeys: Neurochemical Mechanisms Studied by Intrastriatal Microdialysis

  2008cited by this paper
• BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease

  2008cited by this paper
• Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.

  2008cited by this paper
• Molecular mechanisms of L-DOPA-induced dyskinesia

  2008cited by this paper
• TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis.

  2007cited by this paper
• Critical Involvement of cAMP/DARPP-32 and Extracellular Signal-Regulated Protein Kinase Signaling in l-DOPA-Induced Dyskinesia

  2007cited by this paper
• Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

  2007cited by this paper
• 2.016 The severity of L-DOPA-induced dyskinesia in the rat is positively correlated with the density of striatal serotonin afferents

  2007cited by this paper
• Advances in understanding L-DOPA-induced dyskinesia.

  2007cited by this paper
• Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.

  2007cited by this paper
• Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.

  2007cited by this paper
• 2.506 The severity of L-DOPA-induced dyskinesia in the rat is positively correlated with the density of striatal serotonin afferents

  2007cited by this paper
• Levodopa-induced dyskinesias. The clinical problem, clinical features, incidence, risk factors, management and impact on Quality of Life

  2006cited by this paper
• Recent breakthroughs in basal ganglia research

  2006cited by this paper
• Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.

  2006cited by this paper
• Endothelial Proliferation and Increased Blood–Brain Barrier Permeability in the Basal Ganglia in a Rat Model of 3,4-Dihydroxyphenyl-l-Alanine-Induced Dyskinesia

  2006cited by this paper
• Post‐ versus presynaptic plasticity in L‐DOPA‐induced dyskinesia

  2006cited by this paper
• New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity.

  2005cited by this paper
• Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease

  2005cited by this paper
• Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway

  2004cited by this paper
• Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia.

  2004cited by this paper
• Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system

  2004cited by this paper
• BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders.

  2004cited by this paper
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia

  2003cited by this paper
• Prolonged exercise induces angiogenesis and increases cerebral blood volume in primary motor cortex of the rat.

  2003cited by this paper
• D1 Dopamine Receptor Supersensitivity in the Dopamine-Depleted Striatum Results from a Switch in the Regulation of ERK1/2/MAP Kinase

  2002cited by this paper
• The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory

  2001cited by this paper
• BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization

  2001cited by this paper
• Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.

  2001cited by this paper
• Pathological features of cerebral cortical capillaries are doubled in Alzheimer’s disease and Parkinson’s disease

  2000cited by this paper
• Blood vessels change in the mesencephalon of patients with Parkinson's disease.

  1999cited by this paper
• Risk factors for levodopa-induced dyskinesias in Parkinson’s disease

  1999cited by this paper
• Blood vessels change in the mesencephalon of patients with Parkinson's disease.

  1999cited by this paper
• Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats.

  1999cited by this paper
• Levodopa therapy

  1998cited by this paper
• Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age.

  1989cited by this paper

• Evaluation of the potential therapeutic effect of africanized honeybee venom (Apis mellifera Linnaeus) on levodopa-induced dyskinesias in mice.

  2025cites this paper
• Remodeling of Perineuronal Nets in the Striato-Cortical Axis in L-DOPA-Induced Dyskinesia Rat Model

  2025cites this paper
• CBD’s potential impact on Parkinson’s disease: An updated overview

  2024cites this paper
• Construct, Face, and Predictive Validity of Parkinson’s Disease Rodent Models

  2024cites this paper
• Unveiling differential gene co-expression networks and its effects on levodopa-induced dyskinesia

  2024cites this paper
• Impaired cognitive and motor function are coincident with l-DOPA-induced dyskinesia in a model of Parkinson’s disease

  2023cites this paper
• Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia

  2022cites this paper
• MSC-Derived Exosomes can Enhance the Angiogenesis of Human Brain MECs and Show Therapeutic Potential in a Mouse Model of Parkinson's Disease

  2021cites this paper
• Adult Endogenous Dopaminergic Neuroregeneration Against Parkinson’s Disease: Ideal Animal Models?

  2020cites this paper
• Maternal stress programs accelerated aging of the basal ganglia motor system in offspring

  2020cites this paper
• Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia

  2019cites this paper
• Cardinal Motor Features of Parkinson’s Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia

  2018cites this paper
• Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.

  2018cites this paper
• Animal models of l-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse

  2018cites this paper
• Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson’s disease

  2018cites this paper
• The impact of metabotropic glutamate receptors into active neurodegenerative processes: A “dark side” in the development of new symptomatic treatments for neurologic and psychiatric disorders

  2017influential citation
• Validation of a New Scoring Scale for Behavioral Assessment of L-Dopa-Induced Dyskinesia in the Rat: A New Tool for Early Decision-Making in Drug Development.

  2017cites this paper
• Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico‐basal ganglia loop circuit in vivo in experimental parkinsonism

  2017cites this paper
• Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.

  2017cites this paper
• l‐DOPA‐induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?

  2016cites this paper
• The clinical heterogeneity of dyskinesia and freezing disorder (freezing of gait) and its management strategies in adults with Parkinson’s disease

  2016cites this paper
• Altérations du système de récompense dans la maladie de Parkinson : relation entre comportement et signatures moléculaires. : Neuropsychopharmacologie.

  2016cites this paper
• Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.

  2016cites this paper
• Targeting the D1-N-methyl-d-aspartate receptor complex reduces l-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats

  2016cites this paper
• Determination of dopamine, serotonin, biosynthesis precursors and metabolites in rat brain microdialysates by ultrasonic-assisted in situ derivatization-dispersive liquid-liquid microextraction coupled with UHPLC-MS/MS.

  2016cites this paper
• Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.

  2016cites this paper
• Cerebellar and Motor Cortical Transcranial Stimulation Decrease Levodopa-Induced Dyskinesias in Parkinson’s Disease

  2015cites this paper
• Effects of (-)-sesamin on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and dopaminergic neuronal cells of Parkinson's disease rat models.

  2015cites this paper
• Dopaminergic Neurons in Parkinson’s Disease

  2014cites this paper
• Cerebellum in Levodopa-Induced Dyskinesias: The Unusual Suspect in the Motor Network

  2014cites this paper
• Modeling dyskinesia in animal models of Parkinson disease.

  2014cites this paper
• Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials

  2014cites this paper
• Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.

  2014cites this paper
• Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release.

  2014cites this paper
• Dopamine Receptors and Levodopa-Induced Dyskinesia

  2014cites this paper
• 5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation

  2013cites this paper
• Neurotoxic effects of berberine on long-term l-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease

  2013cites this paper
• GABA Attenuates L-DOPA-Induced Striatal and Nigral ERK1/2 Signaling in a Rat Model of Parkinson’s Disease

  2013cites this paper
• Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons.

  2013cites this paper
• Dopamine and GABA Interaction in Basal Ganglia: GABA-A or GABA-B Receptor Stimulation Attenuates L-DOPA-Induced Striatal and Nigral ERK1/2 Signaling in a Rat Model of Parkinson's Disease

  2013cites this paper
• Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.

  2013cites this paper
• Metabotropic Glutamate Receptors for Parkinson's Disease Therapy

  2013cites this paper
• Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.

  2013cites this paper
• Role of movement in long-term basal ganglia changes: implications for abnormal motor responses

  2013cites this paper
• Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia.

  2012cites this paper
• COMPARISON OF MEMBRANE PERMEABILITIES OF TRACE AMINES AND CORRESPONDING NEUROTRANSMITTERS

  2012cites this paper
• Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.

  2012cites this paper
• Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.

  2011cites this paper
• The Noradrenergic System is a Major Component in Parkinson’s Disease

  2011cites this paper
• Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.

  2011cites this paper
• Nitric oxide modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.

  2011cites this paper
• Optimisation and mechanistic insights of dyskinesia in rodent models of Parkinson’s disease

  2011cites this paper
• Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.

  2010cites this paper
• A Model Based Approach to Apraxia in Parkinson's Disease

  2010cites this paper
• Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.

  2008cites this paper